Table 2.
Point Prevalence of Cancer Therapy–Related Cardiac Dysfunction According to the International Cardio-Oncology Society Definition Using the Sex-Specific Cardiac Troponin T 99th Percentile
| After 1 Cycle (n = 115) | After Anthracyclines (n = 115) | After Trastuzumab or Radiation Therapy (n = 81) | Extended Follow-Up (n = 103) | |
|---|---|---|---|---|
| Symptomatic | ||||
| Moderate | 0 (0) | 0 (0) | 0 (0) | 1 (1.0) |
| Asymptomatic | ||||
| Severe | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Moderate | 0 (0.0) | 0 (0.0) | 1 (1.2) | 0 (0.0) |
| Mild | 1 (0.9) | 55 (47.8) | 11 (13.6) | 10 (9.7) |
| Total | 1 (0.9) | 55 (47.8) | 12 (14.8) | 11 (10.7) |
Values are n (%).